Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases
| Autor: | Clinton Mijnals, Karen Bolhuis, Cornelis J. A. Punt, Pien M. Delis-van Diemen, Rutger-Jan Swijnenburg, Daan van den Broek, J. Huiskens, Remond J.A. Fijneman, Gerrit A. Meijer, Marta Lopez-Yurda, Iris van 't Erve, Aysun Komurcu |
|---|---|
| Přispěvatelé: | Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, CCA - Cancer biology and immunology, Oncology |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Tumour regression medicine.medical_specialty Medicine (General) Colorectal cancer Gastroenterology General Biochemistry Genetics and Molecular Biology Resection Tumour tissue Liver metastases Postoperative Complications R5-920 Recurrence free survival Internal medicine Biomarkers Tumor Medicine Pathologic Response Humans In patient Recurrences Postoperative Period Aged business.industry Proportional hazards model Liver Neoplasms General Medicine Middle Aged medicine.disease Survival Analysis Female Neoplasm Recurrence Local business Colorectal Neoplasms Cell-Free Nucleic Acids Circulating tumour DNA Research Paper |
| Zdroj: | EBioMedicine, 70:103498. Elsevier BV EBioMedicine, Vol 70, Iss, Pp 103498-(2021) EBioMedicine |
| ISSN: | 2352-3964 |
| Popis: | BACKGROUND Recurrence rates after resection of colorectal cancer liver metastases (CRLM) are high and correlate with worse survival. Postoperative circulating tumour DNA (ctDNA) is a promising prognostic biomarker. Focusing on patients with resected CRLM, this study aimed to evaluate the association between the detection of postoperative ctDNA, pathologic response and recurrence-free survival (RFS). METHODS Twenty-three patients were selected from an ongoing phase-3 trial who underwent resection of RAS-mutant CRLM after induction systemic treatment. CtDNA analysis was performed by droplet digital PCR using blood samples collected at baseline, before and after resection. Pathologic response of CRLM was determined via the Tumour Regression Grading system. FINDINGS With a median follow-up of 19.6 months, the median RFS for patients with detectable (N = 6, [26%]) and undetectable (N = 17, [74%]) postoperative ctDNA was 4.8 versus 12.1 months, respectively. Among 21 patients with available tumour tissue, pathologic response in patients with detectable compared to undetectable postoperative ctDNA was found in one of six (17%) and 15 of 15 (100%) patients, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|